Bepirovirsen在治愈慢性乙型肝炎方面,与标准护理相结合,在大规模全球试验中实现其主要目标,取得了令人乐观的成果。 Bepirovirsen showed promising results in curing chronic hepatitis B when combined with standard care, meeting its main goal in a large global trial.

GSK和Ionis制药公司宣布对白皮罗维森(一种慢性乙型肝炎的实验治疗)进行第3阶段试验的结果是积极的,表明在与标准护理相结合的情况下,功能治疗率在统计学上显著上升。 GSK and Ionis Pharmaceuticals announced positive Phase 3 trial results for bepirovirsen, an experimental treatment for chronic hepatitis B, showing a statistically significant increase in functional cure rates when combined with standard care. 在两次全球试验中,在1 800多名病人中测试了这一药物,该药物达到其主要终点,治疗后持续丧失乙型肝炎表面抗原和无法检测的病毒DNA。 The drug, tested in over 1,800 patients across two global trials, met its primary endpoint with sustained loss of hepatitis B surface antigen and undetectable viral DNA after treatment. Bepirovirsen, 一种抗血清寡核分裂剂, 展示了一种有利的安全特征, 并可能提供限量的、为期六个月的治疗方案。 Bepirovirsen, an antisense oligonucleotide, demonstrated a favorable safety profile and may offer a finite, six-month therapy option. 完整的数据将于2026年初提交监管审查和出版。 Full data will be submitted for regulatory review and publication in early 2026.